AstraZeneca says it is pruning staff at MedImmune, its biologics R&D center
AstraZeneca’s big U.S. subsidiary MedImmune, with 2200 employees, is pruning its workforce as it adds a greater emphasis on its oncology R&D work–but it’s not specifying just many staffers are involved.
Here’s the statement:
In April, AstraZeneca announced the sharpening of our focus on our main therapy areas to prioritize our pipeline and improve efficiency and productivity across the organization. This will see the company allocate additional investment to core areas, particularly oncology. This is a natural progression of our strategy and reflects increased pipeline productivity, as well as the evolving shape of the overall company portfolio with a growing proportion of specialty-care medicines.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.